Chelsea Counsel Company’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $514K | Hold |
208,210
| – | – | 0.26% | 62 |
|
|
2025
Q1 | $414K | Buy |
208,210
+21,430
| +11% | +$42.6K | 0.23% | 72 |
|
|
2024
Q4 | $545K | Buy |
186,780
+108,090
| +137% | +$316K | 0.28% | 61 |
|
|
2024
Q3 | $305K | Buy |
78,690
+1,000
| +1% | +$3.87K | 0.15% | 84 |
|
|
2024
Q2 | $399K | Buy |
77,690
+72,690
| +1,454% | +$374K | 0.2% | 72 |
|
|
2024
Q1 | $35K | Hold |
5,000
| – | – | 0.02% | 124 |
|
|
2023
Q4 | $44.3K | Buy |
5,000
+4,400
| +733% | +$39K | 0.02% | 120 |
|
|
2023
Q3 | $5.72K | Hold |
600
| – | – | ﹤0.01% | 158 |
|
|
2023
Q2 | $8.79K | Hold |
600
| – | – | ﹤0.01% | 152 |
|
|
2023
Q1 | $7.38K | Hold |
600
| – | – | ﹤0.01% | 143 |
|
|
2022
Q4 | $11.1K | Buy |
+600
| New | +$11.1K | 0.01% | 147 |
|